1.08
+0.01(+0.93%)
Currency In USD
| Previous Close | 1.07 |
| Open | 1.07 |
| Day High | 1.1 |
| Day Low | 1.07 |
| 52-Week High | 2.67 |
| 52-Week Low | 0.93 |
| Volume | 7,049 |
| Average Volume | 91,953 |
| Market Cap | 6.37M |
| PE | -0.46 |
| EPS | -2.37 |
| Moving Average 50 Days | 1.29 |
| Moving Average 200 Days | 1.63 |
| Change | 0.01 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.02 as of December 26, 2024 at a share price of $1.08. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $27.38 as of December 26, 2024 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 17, 2024 12:30 PM GMT
Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Both single-dose and multiple-dose expansion trials planned in 2025 AUSTIN, Texas
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 04, 2024 12:30 PM GMT
Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV)
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
GlobeNewswire Inc.
Dec 03, 2024 12:30 PM GMT
Five-year renewable agreement secures reliable cGMP rhenium-186 (Re-186) supply for late-stage clinical and commercial forecastsAUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical